428results about How to "Good content uniformity" patented technology

An extrusion process comprises extruding a material that is flowable when heated and passing the extrudate thus formed through a nozzle 10 to shape the extrudate into a plurality of substantially uniformly shaped elements such as minispheres or minicapsules.

This invention is related to a process for preparing a stabilized form of vitamin D which comprises the steps of: a) dissolving vitamin D in a solution that contains water and at least one surfactant to produce a mixture; b) spraying the mixture onto an inert carrier to produce a wet mass; and c) drying the wet mass obtain the stabilized form of vitamin D.

With regard to compositions derived from active ingredients and other additives in medical, food and industrial fields, there have been problems that the active ingredients cannot be uniformly mixed, and that the active ingredients become segregated and lose uniformity as the active ingredients undergo transport, input, and filling processes. There is provided a cellulose powder which improves the uniformity of compositions containing active ingredients or other additives to prevent segregation of the active ingredients, wherein the cellulose powder contains cellulose I type crystals, has an average particle diameter of less than 30 μm, a powder density of 0.1 to 0.45 g/cm³, a tapping density of 0.1 to 0.5 g/cm³, a repose angle of 35 to 50°, a specific surface of more than or equal to 0.1 m²/g and less than 20 m²/g, an internal friction angle of 36 to 42°, and is a cellulose powder including a secondary flocculation structure in which primary particles are flocculated.

The invention relates to montelukast sodium chewing tablets and a preparation process thereof. The tablets comprise montelukast sodium and a filling agent, a diluting agent, a bonding agent, a disintegrating agent, and a flavoring. The tablets are prepared with a powder direct tabletting method. The fluidity and compressibility are good. The chewing tablets have long-term storage stability. The tablets are used in prevention and long-term treatment of asthma of children aged 2 to 14, and are used in relieving symptoms caused by allergic rhinitis.

An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix, the matrix comprising at least two water swelling polymers, wherein one of the polymers is pregelatinized starch, and wherein another one of the polymers is an anionic polymer.

The invention discloses a cefetamet pivoxil hydrochloride tablet and a preparation method thereof. On the premise of specific active ingredients of the cefetamet pivoxil hydrochloride, the invention takes into account the varieties and dosages of disintegrating agents and joint usage thereof, suitable components and ratios of bonding agents and other filling agents, and the micronization treatment of the raw and auxiliary materials and selection of corresponding optimized process conditions. Experiment results indicate that compared with the prior art, the product of the invention has quick disintegration and dissolution and stable quality.

The invention is directed to the use of an extended release tablet formulation for pramipexole.

The present invention pertains to a sized product, which contains a drug, polyethylene oxide with a molecular weight of 2,000,000 or higher, and a specific size controlling agent for polyethylene oxide (substance with the appropriate plasticity and binding force) and wherein at least the above-mentioned specific size controlling agent is uniformly dispersed in the above-mentioned polyethylene oxide, a controlled-release pharmaceutical composition containing this sized product, and a method of manufacturing a controlled-release pharmaceutical composition containing this sized product.

A controlled-release pharmaceutical composition with good uniformity of content can be presented by using powder particles of polyethtylene oxide with powder properties suitable for tableting, which is obtained by uniform dispersion of the specific size controlling agent for polyethylene oxide of the present invention.

The invention relates to an Entecavir dispersible tablet and the preparation method; wherein, the Entecavir dispersible tablet comprises Entecavir, binder, filler, disintegrating agent, and lubricant; the uniformity of dosage units (A+1.8S) is not larger than 10.0. The preparation method for the dispersible tablet in the invention has the advantages of simple process, and suitability for large-scale industrial production.

The invention discloses a memantine hydrochloride capsule sustained-release preparation, wherein the preparation is composed of two parts, namely, immediate-release grains and sustained-release grains; the sustained-release part is composed of a blank pellet core, a medicine layer and a release control layer; and the immediate-release part is composed of a blank pellet core and a medicine layer. The capsule is uniform in content, good in release effect, stable in blood concentration, good for reducing the toxic and side effects of medicines, and is capable of being used for treating moderate-to-severe Alzheimer-type dementia, and the medicine-taking times of the patient are reduced,.

The invention discloses Tofacitinib citrate tablets composed of Tofacitinib citrate and pharmaceutically acceptable auxiliary materials. The auxiliary materials comprise filler, disintegrating agent, flow aid and coating materials. The filler is microcrystalline cellulose lactose premix with the model of Celactose80, and the weight ratio of the Tofacitinib citrate to the microcrystalline cellulose lactose premix with the model of Celactose80 is 1:5-25. The invention further discloses a preparation method. The Tofacitinib citrate tablets has high content uniformity and have the advantages of being high in dissolving-out speed, stable in chemical property and the like.

The invention discloses an immunomodulator slow-release preparation and a preparation method thereof. A lenalidomide slow-release tablet is composed of a slow-release layer and an optional quick-release layer, wherein the slow-release layer contains active ingredients of lenalidomide and a slow-release framework material simultaneously; the quick-release layer does not contain the slow-release framework material. The lenalidomide slow-release tablet disclosed by the invention is capable of slowly and uniformly releasing medicines by virtue of the slow-release framework material, so as to reduce the release speed, delay the time to peak, prolong the action time of lenalidomide, and provide a uniform and constant blood concentration. Moreover, The lenalidomide slow-release tablet disclosed by the invention is simple in prescription and excellent in quality stability; the preparation process is simple to operate, free from special treatment and production equipment, low in production cost, and beneficial to batch-enlarged industrial production for the product; the preparation method is high in yield, the granulation and crushing procedures are simple and practicable to operate, the intermediate material is good in stability, flowability, compressibility and content uniformity, and completely meets the requirements of tabletting, and the surface of the prepared tablet is smooth and beautiful.

The invention relates to a solid dispersoid comprising progestational hormone and at least one water-soluble carrier material, wherein the progestational hormone is dispersed into the water-soluble carrier material, and the weight ratio of the progestational hormone to the water-soluble carrier material is 1:0.3-300. The solid dispersoid has the advantages of higher dissolution rate and bioavailability, good content uniformity degree, high physical stability and high chemical stability. The invention also relates to a preparation method of the solid dispersoid and a composite comprising the solid dispersoid.

The invention relates to the technical field of medicine, in particular to diclofenac sodium sustained release tablets and a preparation process thereof. The diclofenac sodium sustained release tablets provided by the invention comprise the following components in percentage by mass: 16.5 to 39.0 percent of diclofenac sodium, 10.0 to 35.5 percent of sustained release agent, 33.5 to 65.0 percent of filling agent, 2.01 to 8.0 percent of glidant, 0 to 2.5 percent of lubricating agent, and 0 to 8.0 percent of adhesive. According to the diclofenac sodium sustained release tablets and a whole-powder direct tabletting method thereof provided by the invention, by changing the components and the preparation method, the production process is simplified, the production cost is reduced, the production efficiency is improved, the yield is improved to 98.0 to 100 percent, granule condensation is avoided, the surface of the tablets is smooth, meanwhile, consumption of high-concentration alcohol is avoided, and the potential safety hazard in the production process is reduced.

The invention relates to an enteric-coated tablet of S-pantoprazole or salt of the S-pantoprazole, and a preparation method thereof, wherein the enteric-coated tablet comprises the components: a) a tablet core formed by the S-pantoprazole or the salt of the S-pantoprazole and pharmaceutic adjuvant; b) an isolating layer; and c) an enteric layer. The tablet core of the S-pantoprazole or the salt of the S-pantoprazole is formed by directly tabletting full powder, so that the damage of high temperature to the S-pantoprazole or the salt of the S-pantoprazole in the process of drying water and granules during wet granulation can be effectively avoided, and the stability of the preparation is improved. Furthermore, the isolating layer and the enteric layer have less composition, so that the preparation is simple and convenient. According to the invention, the preparation technology is simplified and the production cost is reduced; and the prepared S-pantoprazole enteric-coated tablet is better in dissolution rate and good in stability.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a preparation containing vitamin D3 and calcium carbonate and a preparation method for the preparation. The preparation containing vitamin D3 and calcium carbonate comprises calcium carbonate, vitamin D3 and pharmaceutically acceptable auxiliary materials, wherein the vitamin D3 is vitamin D3 coating powder obtained by coating vitamin D3 with opadry. The vitamin D3 coating powder in the preparation containing vitamin D3 and calcium carbonate has relatively good stability, and is relatively high in uniformity of content of vitamin D3. Meanwhile, the preparation containing vitamin D3 and calcium carbonate provided by the invention can effectively promote absorption, on calcium, of a human body.

The invention relates to an Entecavir tablet. The Entecavir tablet contains 0.2-1% of Entecavir monohydrate, 85-98% of filler, 0-5% of binder, 0-10% of disintegrating agent, 0-2% of flow aid and 0.5-2% of lubricating agent by weight, wherein the Entecavir monohydrate is added in the form of powder. The invention also relates to a preparation method of the Entecavir tablet.

The invention designs an anti-depression drug flupentixol-melitracen pharmaceutical composition and a preparation method thereof, wherein the composition comprises flupentixol hydrochloride, melitracen hydrochloride, a filler, a binder, a lubricant and a stabilizer, and is prepared by using wet granulation tableting, and the method comprises: granulation, drying, granulation and total mixing, tableting, film coating, and other steps. According to the present invention, the process effectively solves the problems of dissolution and content uniformity due to the high difference in the contents of the two main drugs, and further protects the stability of the active ingredient; and the prepared flupentixol-melitracen tablet has characteristics of stable quality, safety and good effectiveness.